Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile

Christine W Bruggeman, Gillian Dekkers, Arthur E H Bentlage, Louise W Treffers, Sietse Q Nagelkerke, Suzanne Lissenberg-Thunnissen, Carolien A M Koeleman, Manfred Wuhrer, Timo K van den Berg, Theo Rispens, Gestur Vidarsson, Taco W Kuijpers

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Abs of the IgG isotype are glycosylated in their Fc domain at a conserved asparagine at position 297. Removal of the core fucose of this glycan greatly increases the affinity for FcγRIII, resulting in enhanced FcγRIII-mediated effector functions. Normal plasma IgG contains ∼94% fucosylated Abs, but alloantibodies against, for example, Rhesus D (RhD) and platelet Ags frequently have reduced fucosylation that enhances their pathogenicity. The increased FcγRIII-mediated effector functions have been put to use in various afucosylated therapeutic Abs in anticancer treatment. To test the functional consequences of Ab fucosylation, we produced V-gene-matched recombinant anti-RhD IgG Abs of the four different subclasses (IgG1-4) with and without core fucose (i.e., 20% fucose remaining). Binding to all human FcγR types and their functional isoforms was assessed with surface plasmon resonance. All hypofucosylated anti-RhD IgGs of all IgG subclasses indeed showed enhanced binding affinity for isolated FcγRIII isoforms, without affecting binding affinity to other FcγRs. In contrast, when testing hypofucosylated anti-RhD Abs with FcγRIIIa-expressing NK cells, a 12- and 7-fold increased erythrocyte lysis was observed with the IgG1 and IgG3, respectively, but no increase with IgG2 and IgG4 anti-RhD Abs. Notably, none of the hypofucosylated IgGs enhanced effector function of macrophages, which, in contrast to NK cells, express a complex set of FcγRs, including FcγRIIIa. Our data suggest that the beneficial effects of afucosylated biologicals for clinical use can be particularly anticipated when there is a substantial involvement of FcγRIIIa-expressing cells, such as NK cells.

Original languageEnglish
Pages (from-to)204-211
Number of pages8
JournalJournal of Immunology
Volume199
Issue number1
DOIs
Publication statusPublished - 1 Jul 2017

Cite this

Bruggeman, C. W., Dekkers, G., Bentlage, A. E. H., Treffers, L. W., Nagelkerke, S. Q., Lissenberg-Thunnissen, S., ... Kuijpers, T. W. (2017). Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile. Journal of Immunology, 199(1), 204-211. https://doi.org/10.4049/jimmunol.1700116